Dermatology

A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS)

Condition:   Hidradenitis Suppurativa
Interventions:   Drug: Guselkumab dose 1;   Drug: Guselkumab dose 2;   Drug: Guselkumab dose 3;   Drug: Placebo
Sponsor:   Janssen Research & Development, LLC
Not yet recruiting
ClinicalTrials.gov: Dermatology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

August 16, 2018 / by / in
Pain Outcomes Following Intralesional Corticosteroid Injections

Conditions:   Keloid;   Alopecia Areata;   Acne;   Hypertrophic Scar;   Epidermal Inclusion Cyst;   Frontal Fibrosing Alopecia;   Lichen Plano-Pilaris;   Keratoacanthoma;   Plaque Psoriasis;   Lichen Simplex Chronicus;   Prurigo Nodularis;   Nummular Eczema;   Granuloma Annulare;   Morphea;   Lichen Planus
Interventions:   Drug: Corticosteroid with lidocaine;   Drug: Corticosteroid with normal saline
Sponsor:   Vanderbilt University Medical Center
Not yet recruiting
ClinicalTrials.gov: Dermatology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

August 15, 2018 / by / in
Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects

Conditions:   Dermatitis;   Dermatitis, Atopic;   Eczema;   Skin Diseases;   Skin Diseases, Genetic;   Genetic Diseases, Inborn;   Skin Diseases, Eczematous;   Hypersensitivity;   Hypersensitivity, Immediate;   Immune System Diseases
Interventions:   Drug: PF-04965842 100 mg;   Drug: PF-04965842 200 mg;   Drug: Placebo
Sponsor:   Pfizer
Recruiting
ClinicalTrials.gov: Dermatology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

August 14, 2018 / by / in
An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate to Severe Plaque Psoriasis

Condition:   Psoriasis
Interventions:   Drug: BMS-986165;   Other: Placebo;   Drug: Apremilast
Sponsor:   Bristol-Myers Squibb
Not yet recruiting
ClinicalTrials.gov: Dermatology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

August 10, 2018 / by / in